1801 – Autologous Skin Cell Suspension for the treatment of acute burn wounds in paediatric and adult patients

Health Technology Analysts Pty Limited on behalf of AVITA Medical, Inc

Change to existing Medicare Benefits Schedule items.

The proposed medical service includes the preparation and application of an autologous skin cell suspension for definitive closure of burn wounds greater than or equal to 20% total body surface area.

Type: Therapeutic technology

Severe burns defined as greater than 20% total body surface area requiring treatment are categorised as either: 
1. Deep partial-thickness, which extends further into dermis (reticular dermis) 
2. Full-thickness burns, where the epidermis and dermis are destroyed, producing irretrievable skin loss.
(Reference: Warby and Maani 2023)

However, most severe burn wounds greater than 20% total body surface area do not have a uniform depth throughout the affected area and are often classified as mixed depth.

Provide your input online

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Bypassing PASC
• Pre-MSAC consultation deadline: Friday 13 June 2025 11:59 pm AEST  

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: Bypassing PASC
• ESC meeting: 12-13 June 2025
• MSAC meeting: 31 July - 1 August 2025

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.